Globally, the world spends about $5T on health care and about 65% of therapy decisions are based on the results of diagnostics tests.
Westborough, MA (PRWEB) March 14, 2011
A panel discussion on whole genome sequencing and molecular diagnostics has been added to the 2011 X-Gen Congress. Remote Webcast is available through NGS Leaders, a new community created to advance the use and value of next-generation sequencing.
Panel Session Title:
Whole Genome Sequencing Applied to Clinical Diagnostics -- the Significance to the Research Community
Location: X-Gen Congress and Expo, Hilton San Diego Resort, San Diego, CA
When: Friday, March 18, 2011 from 11:00am-11:50 am PST
Remote Webcast: NGS Leaders
Whole-genome sequencing applied to diagnostics holds great promise for health care. Globally, the world spends about $5T on health care and about 65% of therapy decisions are based on the results of diagnostics tests.
With the precipitous fall in the cost of sequencing, whole-genome sequencing may soon become practical – even common – for reporting on patient susceptibility, diagnosis, and treatment of genetic disorders. Benefits of this advance to medical professionals and patients include: higher precision, ability to detect complex/multi-gene conditions, far lower long-term costs for patients, economies of scale for instrument manufacturers, higher quality/repeatability for laboratories, and faster delivery/approval of research discoveries.
Included in this panel discussion is a demonstration of a newly released capability to analyze/report on a patient’s disease susceptibility, diagnosis, and treatment on over 2000 disorders from a single whole-genome sequence.
Topics and questions addressed by this panel:
- What research and technological developments will help drive this advance?
- How can we better integrate research and clinical efforts/data to accelerate "translation"?
- What does this mean for researchers and their organizations?
- What are the top research bottlenecks/concerns and what can be done to address them?
- Resnick Richard Resnick, CEO, GenomeQuest (Moderator)
- Eliot Shearer, University of Iowa Carver College of Medicine
- Harry Glorikian, CEO, Scientia Advisors
- Michael Moradian, PhD, Molecular Diagnostics, Kaiser Permanente
- Greg Heath, PhD, Senior Vice President and General Manager, Diagnostics, Illumina
- Eric Glazer, Managing Director, NGS Leaders (Host)
Video: video available for replay after the panel.
# # #